Vermillion Board of Directors Elects James T. LaFrance as Chairman
News Dec 16, 2013
Vermillion, Inc. has announced that James T. LaFrance has been appointed a member of its board and was elected chairman of the board on December 12, 2013.
Pursuant to the equity financing transaction announced on May 9, 2013, LaFrance was nominated by Jack W. Schuler, Vermillion's largest private shareholder.
"We value the executive leadership expertise in the diagnostic industry Jim brings as our board chairman," commented Tom McLain, Vermillion's president and CEO. "His experience and proven ability to develop IVD strategies, launch diagnostic products and direct go-to-market strategies at GE Healthcare, Ventana and Bayer Diagnostics fit well with our operational focus to drive broader adoption of our OVA1 test."
LaFrance has almost 30 years of diagnostic industry experience. Most recently, he was head of digital pathology and acting CEO of Omnyx, LLC for GE Healthcare. Prior to that, he held a series of commercial, strategic marketing and business development leadership roles at Ventana Medical Systems (now Roche Tissue Diagnostics), including general manager of their North American and International commercial organizations.
Prior to Ventana, LaFrance served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He was a member of the board at Mitomics, Inc. from 2010 to 2011. He earned a Bachelor of Arts degree in Economics from the University of Connecticut and an MBA from the University of Notre Dame.
LaFrance succeeds Bruce A. Huebner who is retiring from the board. Dr. William Wallen has also retired from the board.
"The board of directors and management team at Vermillion thank Bruce and Bill for their contributions to the company's success," said McLain. "I want to acknowledge Bill Wallen for his technical guidance in support of OVA1 and the development of our next generation diagnostic tests. Bruce Huebner led a significant period of transition at the company as interim CEO and chairman of the board. His contributions of marketing and sales expertise have helped redefine Vermillion's commercial strategy. We wish them both well in their future endeavors."
Following these changes the total number of board directors is six, all serving independently.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018